Rho-Kinase II Inhibitory Potential of Eurycoma longifolia New Isolate for the Management of Erectile Dysfunction

Table 1

Effect of aqueous extract (AE), fractions and isolates on percentage inhibition of ROCK-II activity.

Treatment (s)	Concentrations (µg/ml)	% of inhibition of ROCK-II ± SD
Control	-	0
Vehicle control	5%	2.06 ± 0.075
AE	10	81 ± 0.21
AE	1	62.8 ± 0.84
AE	0.1	16.3 ± 1.26
AE	0.01	3.18 ± 2.4
MeCl	10	86.3± 0.71
MeCl	1	76.8 ± 0.84
MeCl	0.1	46.9 ± 0.56
MeCl	0.01	17.2 ± 1.27
D1	10	90.1± 0.84
D1	1	76.3 ± 1.69
D1	0.1	55.8 ± 0.14
D1	0.01	21.1 ± 1.83
D2	10	86.1± 0.42
D2	1	74.04 ± 0.01
D2	0.1	49.65 ± 0.21
D2	0.01	18.9 ± 3.39
D3	10	90.25± 0.07
D3	1	80.15 ± 0.48
D3	0.1	61.8 ± 0.42
D3	0.01	17.9 ± 1.83
D4	10	87.05± 0.21
D4	1	74.05 ± 0.35
D4	0.1	46.1 ± 4.37
D4	0.01	14.5 ± 1.98
T1	10	60.3 ± 0.14
T1	1	27.35 ± 2.47
T1	0.1	13.3 ± 2.26
T1	0.01	2.78 ± 1.84
T2	10	82.1 ± 0.63
T2	1	68.5 ± 0.35
T2	0.1	33.2 ± 1.55
T2	0.01	10.62 ± 2.94
T3	10	77.1 ± 0.11
T3	1	66.15 ± 0.07
T3	0.1	25 ± 2.47
T3	0.01	10.1 ± 3.34
T4	10	76.2 ± 3.53
T4	1	54 ± 0.42
T4	0.1	25.7 ± 2.47
T4	0.01	6.13 ± 0.44
T5	10	74.5 ± 1.27
T5	1	55.3 ± 0.45
T5	0.1	23.6 ± 2.4
T5	0.01	8.1 ± 2.27
T6	10	78.3 ± 0.38
T6	1	57.1 ± 0.56
T6	0.1	26.4 ± 2.61
T6	0.01	5.4 ± 3.74
T7	10	74.1 ± 2.97
T7	1	49.6 ± 7.89
T7	0.1	19.4 ± 0.14
T7	0.01	5.85 ± 2.93
T8	10	71.4 ± 2.54
T8	1	46.5 ± 1.62
T8	0.1	17 ± 0.77
T8	0.01	4.06 ± 3.8
Y-27632	10	89.9± 0.42
Y-27632	1	68.15 ± 2.75
Y-27632	0.10	42.15 ± 2.19
Y-27632	0.01	22.5 ± 1.27

AE: aqueous extract; D1: water (100%); D2: methanol-water (50%); D3: methanol-water (75%); D4: methanol (100%) diaion fractions; MeCl: methylene chloride fraction; T1: stigmasterol; T2: trans-coniferyl aldehyde; T3: scopoletin; T4: eurycomalactone; T6: 6α- hydroxyeurycomalactone; T6: eurycomanone; T7: eurycomanol; T8: and eurycomanol-2-O-β-D-glucopyranoside.
Significant from Vehicle control at P < 0.0001